Adaptimmune Therapeutics Stock Forecast, Price & News

Adaptimmune Therapeutics (NASDAQ:ADAP) Frequently Asked Questions

Is Adaptimmune Therapeutics a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adaptimmune Therapeutics in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Adaptimmune Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADAP, but not buy additional shares or sell existing shares.
View analyst ratings for Adaptimmune Therapeutics or view top-rated stocks.

How has Adaptimmune Therapeutics' stock price been impacted by Coronavirus?

Adaptimmune Therapeutics' stock was trading at $2.94 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ADAP stock has increased by 22.1% and is now trading at $3.59.
View which stocks have been most impacted by COVID-19.

When is Adaptimmune Therapeutics' next earnings date?

Adaptimmune Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Adaptimmune Therapeutics.

How were Adaptimmune Therapeutics' earnings last quarter?

Adaptimmune Therapeutics plc (NASDAQ:ADAP) issued its quarterly earnings results on Thursday, November, 4th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by $0.04. Adaptimmune Therapeutics had a negative net margin of 2,499.92% and a negative trailing twelve-month return on equity of 53.31%. During the same quarter last year, the firm earned ($0.23) earnings per share.
View Adaptimmune Therapeutics' earnings history.

What price target have analysts set for ADAP?

5 Wall Street analysts have issued 12-month price objectives for Adaptimmune Therapeutics' stock. Their forecasts range from $4.00 to $15.00. On average, they expect Adaptimmune Therapeutics' share price to reach $8.40 in the next year. This suggests a possible upside of 134.0% from the stock's current price.
View analysts' price targets for Adaptimmune Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Adaptimmune Therapeutics' key executives?

Adaptimmune Therapeutics' management team includes the following people:

• Adrian Rawcliffe, Chief Executive Officer & Director (LinkedIn Profile)
• William C. Bertrand, Chief Operating Officer
• Gavin Wood, Chief Financial Officer
• Elliot Norry, Chief Medical Officer
• Helena Katrina Tayton-Martin, Chief Business Officer

What is Adrian Rawcliffe's approval rating as Adaptimmune Therapeutics' CEO?

6 employees have rated Adaptimmune Therapeutics CEO Adrian Rawcliffe on Glassdoor.com. Adrian Rawcliffe has an approval rating of 100% among Adaptimmune Therapeutics' employees. This puts Adrian Rawcliffe in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Adaptimmune Therapeutics' key competitors?

Some companies that are related to Adaptimmune Therapeutics include Ginkgo Bioworks (DNA), BioCryst Pharmaceuticals (BCRX), Editas Medicine (EDIT), Revolution Medicines (RVMD), Vericel (VCEL), NanoString Technologies (NSTG), C4 Therapeutics (CCCC), Alector (ALEC), Sorrento Therapeutics (SRNE), Krystal Biotech (KRYS), Atara Biotherapeutics (ATRA), Inhibrx (INBX), REGENXBIO (RGNX), Coherus BioSciences (CHRS) and Replimune Group (REPL).
View all of ADAP's competitors.

What other stocks do shareholders of Adaptimmune Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adaptimmune Therapeutics investors own include Zynerba Pharmaceuticals (ZYNE), CA (CA), Endologix (ELGX), Brainstorm Cell Therapeutics (BCLI), Second Sight Medical Products (EYES), Shopify (SHOP), Micron Technology (MU), BlackRock (BLK), Cara Therapeutics (CARA) and Chipotle Mexican Grill (CMG).

When did Adaptimmune Therapeutics IPO?

(ADAP) raised $150 million in an initial public offering (IPO) on Wednesday, May 6th 2015. The company issued 9,400,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, Cowen and Company and Leerink Partners served as the underwriters for the IPO and Guggenheim Securities was co-manager.

What is Adaptimmune Therapeutics' stock symbol?

Adaptimmune Therapeutics trades on the NASDAQ under the ticker symbol "ADAP."

Who are Adaptimmune Therapeutics' major shareholders?

Adaptimmune Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (8.22%), Rock Springs Capital Management LP (1.40%), Millennium Management LLC (1.02%), Marshall Wace LLP (1.00%), BlackRock Inc. (0.81%) and Rafferty Asset Management LLC (0.47%). Company insiders that own Adaptimmune Therapeutics stock include Adrian Rawcliffe, Elliot Norry, Gavin Wood, James Noble, John Lunger, Lawrence M Alleva, Peter W Sonsini and William C Bertrand, Jr.
View institutional ownership trends for Adaptimmune Therapeutics.

Which major investors are selling Adaptimmune Therapeutics stock?

ADAP stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Morgan Stanley, Healthcare of Ontario Pension Plan Trust Fund, SG Americas Securities LLC, Rafferty Asset Management LLC, Goldman Sachs Group Inc., GSA Capital Partners LLP, and Citigroup Inc.. Company insiders that have sold Adaptimmune Therapeutics company stock in the last year include Adrian Rawcliffe, Elliot Norry, John Lunger, and William C Bertrand, Jr.
View insider buying and selling activity for Adaptimmune Therapeutics or view top insider-selling stocks.

Which major investors are buying Adaptimmune Therapeutics stock?

ADAP stock was bought by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Baillie Gifford & Co., Millennium Management LLC, Rock Springs Capital Management LP, Eversept Partners LP, BlackRock Inc., Balyasny Asset Management LLC, and Balyasny Asset Management LLC. Company insiders that have bought Adaptimmune Therapeutics stock in the last two years include Gavin Wood, Lawrence M Alleva, Peter W Sonsini, and William C Bertrand, Jr.
View insider buying and selling activity for Adaptimmune Therapeutics or or view top insider-buying stocks.

How do I buy shares of Adaptimmune Therapeutics?

Shares of ADAP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Adaptimmune Therapeutics' stock price today?

One share of ADAP stock can currently be purchased for approximately $3.59.

How much money does Adaptimmune Therapeutics make?

Adaptimmune Therapeutics has a market capitalization of $560.77 million and generates $3.96 million in revenue each year. The biotechnology company earns $-130.09 million in net income (profit) each year or ($0.99) on an earnings per share basis.

How many employees does Adaptimmune Therapeutics have?

Adaptimmune Therapeutics employs 2,020 workers across the globe.

What is Adaptimmune Therapeutics' official website?

The official website for Adaptimmune Therapeutics is www.adaptimmune.com.

Where are Adaptimmune Therapeutics' headquarters?

Adaptimmune Therapeutics is headquartered at 60 JUBILEE AVENUE MILTON PARK OXFORDSHIRE, ABINGDON X0, OX14 4RX.

How can I contact Adaptimmune Therapeutics?

Adaptimmune Therapeutics' mailing address is 60 JUBILEE AVENUE MILTON PARK OXFORDSHIRE, ABINGDON X0, OX14 4RX. The biotechnology company can be reached via phone at 441235430000, via email at [email protected], or via fax at 44-12-3543-0001.